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Abstract
We describe four solid-organ transplant recipients with donor-derived West Nile virus (WNV) 
infection (encephalitis 3, asymptomatic 1) from a common donor residing in a region of increased 
WNV activity. All four transplant recipients had molecular evidence of WNV infection in their 
serum and/or cerebrospinal fluid (CSF) by reverse transcription polymerase chain reaction (RT-
PCR) testing. Serum from the organ donor was positive for WNV IgM but negative for WNV 
RNA, whereas his lymph node and spleen tissues tested positive for WNV by RT-PCR. 
Combination therapy included intravenous immunoglobulin (4 cases), interferon (3 cases), fresh 
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frozen plasma with WNV IgG (2 cases), and ribavirin (1 case). Two of the four transplant 
recipients survived.
Review of the 20 published cases of organ-derived WNV infection found that this infection is 
associated with a high incidence of neuroinvasive disease (70%) and severe morbidity and 
mortality (30%). Median time to onset of symptomatic WNV infection was 13 days after 
transplantation (range 5–37 days). Initial unexplained fever unresponsive to antibiotic therapy 
followed by rapid onset of neurologic deficits was the most common clinical presentation. 
Confirmation of infection was made by testing serum and CSF for both WNV RNA by RT-PCR 
and WNV IgM by serological assays. Treatment usually included supportive care, reduction of 
immunosuppression, and frequent intravenous immunoglobulin. The often negative results for 
WNV by current RT-PCR and serological assays and the absence of clinical signs of acute 
infection in donors contribute to the sporadic occurrence of donor-derived WNV infection. 
Potential organ donors should be assessed for unexplained fever and neurological symptoms, 
particularly if they reside in areas of increased WNV activity.
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West Nile virus (WNV) is an arthropod-borne, single-stranded RNA flavivirus first observed 
in the United States in 1999 (1). Since 1999, WNV has emerged as the most common cause 
of neuroinvasive arboviral disease in the continental United States (2). West Nile virus 
infection is usually transmitted by mosquitoes that acquire the virus from infected wild birds 
and then spread the virus to humans (3). Approximately 75% of WNV infections in humans 
are asymptomatic (4). However, 25% of humans develop a self-limiting febrile illness (West 
Nile fever), whereas less than 1% experience neuroinvasive disease manifested by 
encephalitis, meningitis, or acute flaccid paralysis (5, 6).
Transmission of WNV infection has also occurred through blood transfusion, breast-feeding, 
transplacental exposure, percutaneous injury in the laboratory, and conjunctival exposure to 
infected avian brain and body fluids (7–11). Transmission of WNV by organ transplantation 
was first reported in 2002 and appears to be associated with a high incidence of severe 
neuroinvasive disease (12, 13). Nonetheless, proven organ-derived WNV infection has 
generally been an uncommon, sporadic occurrence and can easily be overlooked in 
susceptible patients and their organ donors (14). Thus, we report four additional cases of 
organ-derived WNV infection. In addition, we summarize the clinical, diagnostic, and 
therapeutic features of organ-derived WNV infection based on these 4 cases and previously 
published cases of transplant recipients acquiring infection from a WNV-infected donor.
CASE REPORTS AND INVESTIGATION OF WNV TRANSMISSION
Organ Donor
In the early fall of 2011, a 56-year-old man with a history of cerebral palsy, developmental 
cognitive delay, blindness, and seizures, developed fever, muscle weakness, and an altered 
level of consciousness. He was seen in the emergency room of a local hospital, where he was 
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noted to be confused and uncooperative. He was started on an oral antibiotic for a possible 
urinary tract infection and sent home. Final urine and blood cultures were negative. Three 
days later, he became progressively more lethargic and developed a severe cough and 
choking spells. Paramedics were called to his home and found him unresponsive and in 
cardiopulmonary arrest. After intubation and cardiopulmonary resuscitation, he was 
transported to another different local hospital. He was admitted to the intensive care unit, 
placed on a ventilator, and given broad-spectrum antibiotics for possible sepsis. Neurologic 
exam revealed unresponsiveness, absent corneal reflexes, and no spontaneous movements. 
Blood and urine cultures were negative. Computed tomography (CT) scan of the brain 
showed decrease in gray matter and mild cortical edema. Electroencephalogram showed no 
cortical activity consistent with brain death. A lumbar puncture or other studies for central 
nervous system infection were not performed. On hospital day 7, after permission from the 
patient’s mother was obtained, organ procurement occurred.
Patient 1 (Left Kidney Recipient)
A 59-year-old man, with end-stage renal disease due to diabetic nephropathy and requiring 
chronic hemodialysis, received the left donor kidney in hospital A. Baseline 
immunosuppressive therapy consisted of alemtuzumab and corticosteroids, followed by 
tacrolimus plus mycophenolate. After initial slow recovery of kidney graft function 
requiring posttransplantation hemodialysis, the patient was discharged home on day+5 after 
transplantation. On day+10, the patient was readmitted to the hospital for fever, myalgias, 
and diarrhea. Cultures were negative, and the fevers persisted despite treatment with 
antibiotics. On day+13, the patient developed lethargy, encephalopathy, tachypnea, and 
hypotension. He was transferred to the intensive care unit and given additional broad-
spectrum antibiotics for possible sepsis. On day+14, tests of cerebrospinal fluid (CSF) 
revealed 698 RBC/mm3, 38 WBC/mm3 with 69% neutrophils, protein of 92 mg/dL, and 
glucose of 44 mg/dL. He was treated with high-dose intravenous acyclovir, ampicillin, and 
doxycycline. On day+15, patient experienced new left-sided weakness followed by coma. 
Magnetic resonance imaging (MRI) of the brain showed evidence of a subacute stroke in the 
left pons. On day+16, when CSF WNV polymerase chain reaction (PCR) was reported 
positive for WNV, the dosages of immunosuppressive drugs were reduced. Other CSF viral 
tests were negative. The United Network for Organ Sharing (UNOS) and Donor Network 
were immediately contacted on day+16 regarding possible donor-derived encephalitis. 
Retrospective testing of CSF for WNV IgM was negative, whereas the serum WNV PCR 
was positive (Table 1). The patient was treated with polyvalent intravenous immunoglobulin 
(500 mg/kg per day from day+15 to day+19) plus subcutaneous interferon alfa-2b (3 million 
units per day from day+19 to day+22). However, the patient remained in a coma and 
developed status epilepticus. On day+23, care was withdrawn. Autopsy was declined.
Patient 2 (Right Kidney Recipient)
A 51-year-old man on hemodialysis for end-stage renal disease due to hypertension received 
the right donor kidney in hospital A. Baseline immunosuppressive therapy consisted of 
thymoglobulin and corticosteroids followed by tacrolimus plus mycophenolate. He was 
discharged home on day+5 after transplantation but required posttransplantation dialysis 
because of delayed kidney graft function. On day+17, he was readmitted to the hospital for 
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fever. Because of the awareness of WNV encephalitis in the other kidney recipient, lumbar 
puncture was performed. Tests of the CSF revealed 355 RBC/mm3, 11 WBC/mm3 with 79% 
neutrophils, and protein of 29 mg/dL. On day+19, he developed headaches and 
disorientation in addition to persistent fever. When both the CSF and serum WNV PCR were 
reported positive (Table 1), his tacrolimus was discontinued. Testing for WNV IgM was 
negative for the CSF but positive for the serum (Table 1). He was treated with polyvalent 
intravenous immunoglobulin (500 mg/kg per day from day+18 to day+21) plus 
subcutaneous interferon alfa-2b (3 million units per day from day+18 day+28). He also 
received infusions of fresh frozen plasma containing WNV IgG on 3 consecutive days. His 
fever resolved, and his mental status returned to normal. On day+30, tacrolimus was 
restarted, and the patient was discharged home. He had no residual neurologic deficits. He 
subsequently developed chronic rejection and is being evaluated for repeat kidney 
transplantation.
Patient 3 (Bilateral Lung Recipient)
A 59-year-old man with interstitial pneumonitis received both donor lungs in hospital B. 
Baseline immunosuppression consisted of basiliximab, corticosteroids, and mycophenolate, 
followed by tacrolimus, corticosteroids, and mycophenolate. His initial posttransplantation 
course was uncomplicated, and he was discharged home on day+10 after transplantation. On 
day+13, he was readmitted to the hospital for dyspnea and hypoxemia. He was given 
diuretics for fluid overload and high-dose corticosteroids for presumed acute cellular 
rejection. There was partial improvement in his clinical condition. On day+20, the patient 
developed encephalopathy, right upper-extremity weakness, and respiratory distress 
requiring intubation. When the transplant physicians were notified of the WNV infections in 
the two kidney recipients from the same donor, the dosages of immunosuppressive drugs 
were reduced. On day+22, tests of CSF revealed 7 RBC/mm3, 1 WBC/mm3, protein of 48 
mg/dL, and glucose of 67 mg/dL. CSF was positive for WNV RNA by PCR and WNV IgM 
by enzyme-linked immunosorbent assay (ELISA) (Table 1). Serum WNV PCR was also 
positive. MRI of the brain and spine showed diffuse leptomeningeal and cauda equina 
enhancement. The patient was treated with polyvalent intravenous immunoglobulin (500 
mg/kg per day on days 20, 22, 23, 25, 26, and 31 posttransplantation; Privigen, CSL 
Behring, King of Prussia, PA or Gamunex, Grifols Therapeutics, Clayton, NC) plus 
subcutaneous interferon alpha-2b (6 million units on day 20 posttransplantation, 3 million 
units per day on days 21, 22, 23, 31, and 32 posttransplantation, and then 1 million units per 
day on days 33, 34, and 35 posttransplantation). Despite these therapies, the patient 
developed complete flaccid paralysis and multiple seizures. He expired on day+38. Autopsy 
revealed severe encephalomyelitis.
Patient 4 (Liver Recipient)
A 63-year-old man with end-stage liver disease due to alcoholic cirrhosis and hepatocellular 
carcinoma received the donor liver in hospital C. The patient was feeling well before 
transplantation and had a model for end-stage liver disease (MELD) score of 33. Baseline 
immunosuppression was tacrolimus, corticosteroids, and mycophenolate. The liver 
transplant surgery was complicated because of multiple adhesions, postperfusion 
coagulopathy, and severe hemorrhage requiring multiple transfusions (50 units of packed red 
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blood cells, 50 units of fresh frozen plasma). The initial posttransplantation course was 
further complicated by delayed graft function, renal failure, and pulmonary edema. On day
+18, the patient developed fever and transient confusion associated with an E. coli urinary 
tract infection treated successfully with piperacillintazobactam. However, when the 
transplant physicians were notified of WNV infection in the two kidney recipients from the 
same donor, an investigation for WNV infection was initiated. Plasma from day+17 was 
positive for WNV IgG but negative for WNV IgM by ELISA and WNV RNA by PCR 
(Table 1). On day+19, tests of CSF showed 11 RBC/mm3, 1 WBC/mm3, protein of 43 
mg/dL, and glucose of 74 mg/dL. Cerebrospinal fluid WNV PCR was positive, but the CSF 
WNV IgM was negative (Table 1). Computed tomographic scan of the brain showed mild 
generalized cerebral atrophy. Patient was subsequently treated with oral ribavirin (600 mg 
every 12 hours) plus polyvalent intravenous immunoglobulin (500 mg/kg daily for 4 doses 
and then 500 mg/kg every other day from day+18 to day+40; Privigen). On day+27, patient 
underwent a second liver transplant surgery for delayed nonfunction of the first graft. WNV 
RT-PCR testing on tissue from the first liver graft was negative. During the next 8 weeks, 
patient had a prolonged hospital course with slow recovery of liver graft function and 
ongoing need for hemodialysis. He never developed any clinical symptoms or signs of 
encephalitis or meningitis. He was finally discharged to a rehabilitation facility and then 
returned home. The patient’s renal function improved, and he is doing well with excellent 
liver graft function.
Investigation and Reporting of WNV Transmission
When physicians in hospital A notified UNOS and the Donor Network of possible donor-
derived encephalitis in the left kidney transplant recipient, the health-care providers for the 
other recipients of organs from the same donor were immediately informed on the same day 
of this likely donor-derived central nervous system infection. A public health investigation 
was also initiated to coordinate WNV testing of these other recipients, to review the donor’s 
history for WNV risk factors, and to test stored serum and tissues for WNV (15).
By late summer 2011, the donor’s county of residence had the highest number of confirmed 
cases of human WNV infection as well as the greatest amount of WNV nonhuman 
surveillance activity within the state. The organ donor had no history of receipt of blood 
products before his hospitalization. The donor’s mother did not recall any definite mosquito 
bites but stated that the doors and windows of their non-air conditioned home were 
frequently left open and were not fitted with screens. The donor occasionally spent time 
sitting in a nearby park.
Testing of the organ donor for WNV infection was not performed as part of the organ donor 
screening process. However, retrospective postdonation testing of the donor’s serum by the 
CDC was positive for both WNV IgM by microsphere-based immunoassay (MIA) and 
WNV IgG by ELISA (Table 1) (16, 17). The donor’s serum WNV plaque reduction 
neutralization antibody titer was positive at 1:160 (18). Taqman reverse transcriptase-PCR 
testing of stored donor’s serum obtained at time of donation was negative for WNV, but 
similar PCR testing on the donor’s lymph nodes and spleen homogenate by the CDC was 
positive for WNV RNA (19).
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None of the four transplant recipients had a recent febrile illness before transplantation. 
Retrospective testing by WNV TaqMan reverse transcriptive-PCR of stored pre-
transplantation serum by the CDC was negative for the two kidney recipients and the liver 
recipient (Table 1). The lung recipient’s pretransplantation serum was not available for PCR 
testing. Tests of pretransplantation serum for WNV IgM in the two kidney recipients and the 
liver recipient by the CDC (by MIA) and in the lung recipient by a local laboratory (by 
ELISA) were all negative.
REVIEW OF CLINICAL, DIAGNOSTIC, AND THERAPEUTIC FEATURES OF 
DONOR-DERIVED WNV INFECTION
There have been seven other published reports of WNV infection transmitted by solid-organ 
transplantation (13, 20–26). One unpublished report of a donor-derived cluster of WNV 
infection among solid-organ transplant recipients has also been noted, but no data are 
provided for analysis (27). The characteristics of the eight published organ donors 
transmitting WNV infection are summarized in Table 2. All the organ donors were adults. 
Six donors resided in areas of increased WNV activity and most likely acquired their 
infection by a mosquito bite. Two donors had WNV infection from a previous blood 
transfusion. Except for the organ donor with cerebral palsy and a recent febrile illness 
described in the present report, none of the organ donors had any symptoms or signs of 
infection at the time of donation. Testing for WNV infection before organ donation was done 
in only one of the eight donors. Because of a high level of WNV infection in northeastern 
Italy, the Italian National Transplant Network instituted a surveillance program in 2008 to 
detect WNV in organ donors in northeastern Italy (24, 25). However, the blood of this tested 
organ donor was negative for WNV by nucleic acid amplification (NAT). In contrast, WNV 
testing of deceased organ donors in the United States is currently not required (28) and, 
therefore, was not done in the other six donors who lived in the United States or in another 
Italian donor before organ procurement (22). Retrospectively, only four (50%) of the eight 
donors tested positive for WNV by serum PCR, and only three of the eight donors (38%) 
tested positive for serum WNV IgM.
A total of 23 transplant recipients receiving organs from donors infected with WNV have 
been published (13, 20–26). Twenty of these transplant recipients (87%) became infected 
with WNV. One kidney recipient, one liver recipient, and one heart recipient each tested 
negative for WNV after transplantation by either serum PCR or serologic tests and remained 
asymptomatic. The clinical characteristics of the 20 published cases of transplant recipients 
with donor-derived WNV infection are summarized in Table 3. The median age was 52 
years. Fifteen of the 20 recipients had received either donor kidney, or liver, organs. Baseline 
immunosuppressive agents usually included tacrolimus and corticosteroids. Seven recipients 
had received antilymphocyte antibodies (antithymocyte globulin, thymoglobulin, 
basiliximab, or alemtuzumab). The median time from transplantation to onset of symptoms 
was 13 days. Fourteen of the 20 transplant recipients (70%) developed encephalitis, one had 
WNV fever, and 5 remained asymptomatic. The most common initial presentation of 
infection was fever and constitutional symptoms (myalgias, arthralgias, fatigue, or diarrhea) 
usually unresponsive to empiric antibiotic therapy and associated with negative bacterial 
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cultures. Only five patients had neurological symptoms (encephalopathy, altered mental 
status, or seizure) as part of the initial presentation of their WNV infection. On the other 
hand, patients developing encephalitis subsequently experienced altered mental status and 
frequent rapid onset of neurological deficits causing dysarthria, flaccid paralysis, seizures, 
and coma. The diagnosis of WNV infection was usually confirmed by testing of both serum 
and CSF for WNV RNA and/or WNV IgM. WNV RNA was detected in the serum of 10 
(83%) of 12 tested patients, whereas serologic testing of serum for WNV IgM was positive 
in 15 (83%) of 18 tested patients.
Cerebrospinal fluid findings in the published cases of donor-derived WNV central nervous 
system infection in transplant recipients are summarized in Table 4. The mean CSF WBC 
was minimally elevated (86 WBC/mm3), with a predilection toward polymorphonuclear 
pleocytosis (mean % of polymorphonuclear cells of 62%). The CSF protein was slightly 
increased (mean protein of 88 mg/dL), whereas the CSF glucose was usually in the normal 
range (mean glucose of 65 mg/dL, range of 44–105 mg/dL). The CSF WNV PCR was 
positive in 6 (75%) of 8 tested patients, whereas serological testing of CSF for WNV IgM 
was positive in 10 of 14 tested patients (71%).
Results of MRI of the brain were reported in six transplant recipients with WNV 
encephalitis and were abnormal in four patients. Abnormalities reported were diffuse 
restriction of the internal capsule; increased signal in the thalamus, basal ganglia, white 
matter, and brain stem; subacute stroke involving the pons; and diffuse leptomeningeal 
enhancement. Results of CT scan of the brain in 3 transplant recipients with asymptomatic 
WNV infection were unremarkable.
The treatment regimens used in the published cases of donor-derived WNV infections are 
summarized in Table 5. Six (30%) of the 20 patients expired or were reported in coma. The 
most common treatment was intravenous immunoglobulin. Both polyvalent intravenous 
immunoglobulin (Privigen, Gamunex, and other products) and a hyperimmune intravenous 
immunoglobulin with high antibody-titers against WNV (Omr-IgG-am, Omrix 
Biopharmaceutical Ltd, Kiryat-Ono, Israel) were used. Three (43%) of seven transplant 
recipients with WNV encephalitis treated with an intravenous immunoglobulin alone or in 
combination with interferon or fresh frozen plasma containing WNV IgG improved. On the 
other hand, five (71%) of seven transplant recipients with encephalitis and receiving only 
supportive care also improved. All four transplant recipients receiving intravenous 
immunoglobulin for asymptomatic WNV infection remained asymptomatic and never 
developed neuroinvasive disease. Only one of three transplant recipients treated with 
interferon survived.
DISCUSSION
This report describes the transmission of WNV infection through organ transplantation to a 
cluster of four solid-organ transplant recipients from a common organ donor, who probably 
recently acquired the infection by a mosquito bite in a geographic area of increased WNV 
activity. Both the organ donor and all four organ transplant recipients had molecular 
evidence of WNV infection in various clinical samples (Table 1). WNV RNA was not 
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detectable in the donor’s pretransplant serum but was found in the donor’s lymph nodes and 
spleen. The organ donor had also experienced a recent acute febrile illness. In contrast, all 
four transplant recipients had been afebrile and clinically stable before transplantation. The 
two kidney recipients and the lung recipient subsequently developed WNV encephalitis 
within the first 3 weeks after transplantation, whereas the liver recipient had detectable 
asymptomatic WNV central nervous system infection very early after transplantation. 
Encephalitis and other central nervous system infections within the first month after solid-
organ transplantation are very uncommon (29). The early occurrence of encephalitis in the 
left kidney transplant recipient in this report alerted the transplant physicians of possible 
donor-derived infection. Immediate reporting of this index case to public health authorities 
and the Organ Procurement and Transplantation Network (OPTN) facilitated the prompt 
initiation of diagnostic and therapeutic procedures in the other patients.
Overall, in published reports, 87% of persons receiving organs from WNV-infected donors 
became infected with WNV. Seventy percent of the infected transplant recipients developed 
encephalitis, whereas only 25% remained asymptomatic. This high incidence of 
neuroinvasive disease is much greater than the less than 1% incidence of neuroinvasive 
disease in immunocompetent people infected with WNV by a mosquito bite (5, 6). 
Furthermore, 30% of the patients with organ-derived WNV infection either expired or were 
reported in coma. This high morbidity and mortality rate is similar to the 18% mortality rate 
among transplant patients with naturally acquired WNV encephalomyelitis (30). Among 
nonimmunocompromised persons with WNV infection, the mortality rate is less than 1% 
(2).
The most common initial clinical presentation of symptomatic donor-derived WNV 
infection in transplant recipients is fever plus constitutional symptoms associated with 
negative routine cultures and unresponsive to antibiotic therapy within the first month after 
transplantation. Although 70% of patients eventually develop encephalitis, only 33% have 
neurologic symptoms at the time of their initial clinical presentation (Table 3). Studies of the 
CSF in those patients with neuroinvasive WNV disease usually show only a modest 
pleocytosis with a predominance of polymorphonuclear cells, a mild elevation of CSF 
protein, and a normal CSF glucose. The CSF WBC counts in these transplant patients with 
donor-derived WNV encephalitis (mean CSF WBC of 86 cells/mm3) are minimally elevated 
compared with the CSF cell counts in immunocompetent patients with WNV encephalitis 
(mean CSF WBC of 227 cells/mm3) but are similar to the CSF WBC counts in transplant 
patients with naturally acquired WNV encephalitis (mean CSF WBC of 89 cells/mm3) (30, 
31). On the other hand, there seems to be no significant difference in the CSF protein and 
glucose concentrations between transplant patients with encephalitis and immunocompetent 
patients with encephalitis (31).
The diagnosis of donor-derived WNV infection in solid-organ transplant patients requires a 
high index of clinical suspicion in any patient who develops unexplained fever followed by 
neurologic symptoms during the early posttransplantation period. Confirmation of the 
diagnosis of WNV infection is usually made by testing both serum and CSF for WNV IgM 
antibodies by serological assays and for WNV RNA by nucleic acid amplification (NAT) 
assays (Table 3). Various NAT tests have been developed for WNV, including RT-PCR and 
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nucleic acid sequence-based amplification (19, 32). Although these NAT assays can be 
useful for acute infection, their results can become negative later in the course of 
symptomatic disease when viral-specific antibodies are detectable (33, 34). The production 
of WNV IgM antibodies commonly follows the decline in WNV viremia but may be blunted 
in patients with defective humoral immunity (35). Some WNV serologic tests may also cross 
react with other flavivirus antigens. A positive IgM result by ELISA or microsphere assay 
can be confirmed by a plaque reduction neutralization test specific for WNV (18).
There is no treatment of proven benefit for WNV infection. Supportive care and temporary 
reduction in immunosuppressive agents have been common approaches. Recently, favorable 
results with intravenous immunoglobulin or pooled immune plasma containing WNV 
antibodies have been described in animal models and in some cases of human infection (22, 
23, 36–42). Efficacy appears greatest when an immunoglobulin preparation or pooled 
immune plasma containing very high titers of anti-WNV antibodies is administered early in 
the course of infection before severe neuroinvasive disease develops. In our review of 
transplant recipients with donor-derived WNV infection, three (43%) of seven patients with 
encephalitis treated with intravenous immunoglobulin alone or with fresh frozen plasma 
containing WNV IgG improved, whereas all four patients with asymptomatic WNV 
infection treated with intravenous immunoglobulin or plasma survived. However, there are 
no results available from controlled trials to determine what proportion of infected patients 
would have developed disease had they not received antibody therapy. Furthermore, five of 
seven transplant recipients (71%) with encephalitis and receiving only supportive care also 
improved. Of note, the liver transplant recipient with asymptomatic CNS WNV infection in 
this report received massive amounts of fresh frozen plasma during the transplant surgery 
and was sero-positive for WNV IgG after transplantation (Table 1). Thus, it is possible that 
he may have received WNV IgG antibodies in the fresh frozen plasma transfusions which 
ameliorated his WNV infection (43).
Both interferon and ribavirin have in vitro antiviral activity for WNV (44). Several case 
reports of the successful treatment of WNV meningoencephalitis with interferon in 
nontransplant patients have been published (45–47). In a small randomized unblinded trial 
of alpha interferon therapy (3 million units subcutaneously each day for 14 days) for WNV 
encephalitis in immunocompetent patients, interferon treated patients had greater neurologic 
improvement compared with untreated patients but also more toxicity (neutropenia, 
hepatitis) (48). Only one of the three transplant patients in this report with organ-derived 
WNV encephalitis treated with interferon survived (Table 5), but there was no apparent 
toxicity. Ribavirin, which shows in vitro activity for WNV only at very high concentrations 
and has limited penetration into the CSF, had no significant benefits in either animal models 
or in normal hosts with WNV infection (49, 50). The liver transplant recipient in this report 
received oral ribavirin for 3 weeks plus intravenous immunoglobulin and survived. The use 
of ribavirin and interferon for WNV infection requires further study.
To avoid the potential morbidity and mortality associated with donor-derived WNV 
infection, identification of potentially infected organ donors is necessary. For living organ 
donors, HRSA and OPTN recommend screening for WNV as close to the time of donation 
as possible (28, 51). On the other hand, because of concerns about false-positive screening 
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results using NAT and potential loss of organs, routine screening of deceased organ donors 
for WNV is not recommended (27, 28, 51). Furthermore, it is not known if WNV screening 
would necessarily decrease transmission of WNV infection. Indeed, only four of the eight 
organ donors associated with published cases of organ-derived WNV infection tested 
positive for WNV infection in their serum by NAT (Table 2). In the one case in Italy where 
the organ donor was screened for WNV at time of organ donation, the patient’s serum tested 
negative for WNV by NAT (24). The organ donor described in this report had WNV RNA in 
his lymph nodes and spleen, although retrospective testing of his serum for WNV by NAT 
and reverse transcription PCR was negative. Thus, current laboratory methods for WNV 
screening of organ donors appear inadequate. Seven of the eight organ donors associated 
with published cases of organ-derived WNV infections had no clinical features of WNV 
disease; however, one donor had a recent febrile illness and mental status changes (Table 2). 
Potential organ donors with unexplained fever and neurologic symptoms should be 
thoroughly evaluated for meningoencephalitis, including testing of CSF for WNV and other 
potential pathogens (52, 53). Deferring donors with fever and neurologic symptoms of 
uncertain etiology should be considered (53). The risk of transmission of a donor-derived 
infection must be balanced with the risk of a poor recipient outcome if the donor is not used. 
Potential organ recipients also need to be advised of the possible risk of donor-derived WNV 
infection even when a high-risk donor tests negative for WNV.
In summary, organ-derived WNV infection is associated with a high incidence of 
neuroinvasive disease. Diagnosis requires a high index of clinical suspicion in a transplant 
recipient with fever and neurologic symptoms within the first month after transplantation. 
WNV infection is confirmed by testing both serum and CSF for WNV RNA and IgM 
antibody. As there is no specific antiviral treatment available, treatment remains supportive; 
reduction in immunosuppressive agents and the use of IV IgG and interferon have been 
reported in the literature, but there is no proven efficacy. Prompt reporting of cases of donor-
derived WNV infection to public authorities can facilitate the diagnosis and treatment in 
other transplant recipients at risk for infection. Data are lacking regarding the sensitivity and 
specificity of available WNV tests when used to screen deceased organ donors, and 
screening of deceased organ donors for WNV is currently not required in the United States. 
However, considering deferral of organ donors with recent fever and unexplained neurologic 
symptoms, especially in areas with known WNV activity, may decrease the risk of WNV 
transmission from an infected organ donor.
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TABLE 2
Characteristics of published organ donors transmitting WNV infection
Characteristic
No. of donors 8
Age
 Mean (range), yr 46 (18–78)
 Median (range), yr 43 (18–78)
Sex
 Male 4
 Female 3
 Not reported 1
Mode of WNV acquisition
 Mosquito 6
 Blood transfusion 2
Residence in area of increased WNV activity
 Yes 6
 No 2
Medical condition leading to organ donation
 Trauma 4
 Cerebral hemorrhage 2
 Gunshot wound 1
 Cerebral palsy, febrile illness 1
WNV testing before donation
 No 7
 Yesa 1
Retrospective WNV testingb
 Positive serum PCR 4/8
 Positive serum IgM 3/8
 Positive serum IgG 4/6
 Positive tissue PCR (lymph node, spleen) 1/1
a
Tested negative by NAT, nucleic acid amplification.
bNo. of donors positive/No. of donors tested.
WNV, West Nile virus; PCR, polymerase chain reaction.
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TABLE 3
Clinical characteristics of published transplant recipients with donor-derived WNV infection
Characteristic (No. of recipients with data)
No. of transplant recipients 20
Age (14)
 Mean (range), yr 52 (25–73)
 Median (range), yr 52 (25–73)
Sex (20)
 Male 10
 Female 4
 Not reported 6
Type of transplant (20)
 Kidney 9
 Liver 6
 Lung 3
 Heart 2
Immunosuppresive agents (13)
 Tacrolimus 12
 Corticosteroids 11
 Mycophenolate 10
 Antilymphocyte antibodies 7
 Cyclosporine 1
 Sirolimus 1
Days from transplant to symptoms (15)
 Mean (range), d 14 (5–37)
 Median (range), d 13 (5–37)
Clinical WNV diagnosis (20)
 Encephalitis 14
 WNV fever 1
 Asymptomatic 5
Initial symptoms (15)
 Fever, constitutional symptoms 10
 Fever, dyspnea 1
 Fever, altered mental status 1
 Altered mental status 1
 Encephalopathy 2
 Seizures 1
Neurological symptoms in patients with WNV encephalitis (11)
 Altered mental status 11
 Dysarthria 4
 Lower extremity weakness 4
 Flaccid paralysis 5
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Characteristic (No. of recipients with data)
 Hemiparesis 2
 Facial nerve palsy 1
 Seizures 4
 Coma 8
WNV testing of serum
 Positive serum PCR 10/12a
 Positive serum IgM 15/18
 Positive serum IgG 5/8
 Positive tissue PCR (brain) 2/2
aNo. of transplant recipients positive/no. of transplant recipients tested.
WNV, West Nile virus; PCR, polymerase chain reaction.
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TABLE 4
Cerebrospinal fluid findings in published transplant recipients with donor-derived WNV infection of central 
nervous system
Parameter No. of patients tested Result
Mean RBC count/mm3 (range) 5 227 (2–698)
Mean WBC count/mm3 (range) 11 86 (0–675)
Mean % of PMN (range) 7 62% (24%–92%)
Mean protein, mg/dl (range) 11 88 (29–149)
Mean glucose, mg/dl (range) 7 65 (44–105)
Positive WNV PCR,
No. positive/No. tested (%)
8 6/8 (75%)
Positive WNV IgM
No. positive/No. tested (%)
14 10/14 (71%)
Positive WNV IgG
No. positive/No. tested (%)
6 3/6 (50%)
WNV, West Nile virus; RBC, red blood cell count; WBC, white blood cell count; PMN, polymorphonuclear neutrophil; PCR, polymerase chain 
reaction.
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TABLE 5
Treatment regimens for donor-derived WNV infection in transplant recipientsa
No. improved/No. treated
Encephalitis (N=14 patients)
 Supportive care 5/7
 IV immunoglobulin alone 1/3
 IV immunoglobulin, fresh frozen immune plasma 1/1
 IV immunoglobulin, fresh frozen immune plasma, interferon 1/1
 IV immunoglobulin, interferon 0/2
WNV fever (N=1 patient)
 Supportive care 1/1
Asymptomatic (N=5 patients)
 IV immunoglobulin alone 2/2
 IV immunoglobulin, fresh frozen immune plasma 1/1
 IV immunoglobulin, ribavirin 1/1
 Supportive care 1/1
a
IV immunoglobulin (polyvalent=6, Omr-IgG-am with high titer WNV antibodies=5).
Fresh frozen immune plasma with WNV IgG antibodies.
Interferon (interferon alfa-2b, subcutaneous).
WNV, West Nile virus.
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